Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Weight-loss, drugs
Sweeping review suggests effect of weight-loss drugs on 175 conditions
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected but contain surprises, too.
Weight-loss drugs may boost health in many ways
The first study to assess how weight-loss drugs affect the whole of human health has discovered an "eye-opening" impact on the body, researchers say. The analysis, involving about two million people,
Benefits and risks of popular weight-loss drugs revealed
Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study reporting one in eight Americans has taken or is currently using the drugs to treat diabetes,
1d
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
1h
on MSN
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...
HealthLeaders Media
1h
Popular weight-loss drugs linked to new health risks and benefits
A large analysis of weight-loss drugs like Ozempic and Wegovy has surprised health researchers, who found links to multiple new benefits – and some new side effects.
52m
Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback